JAMA released more research today that further confirms the importance of CYP2D6 testing to determine tamoxifen efficacy. Full details at http://jama.ama-assn.org/cgi/content/short/302/13/1429.
The conclusion:
Recurrence Rates:
14.9% for extensive metabolizers
20.9% for intermediate metabolizers
29.0% for poor metabolizers
This means that Extensive Metabolizers will get the same preventative outcome from tamoxifen as much more expensive aromatase inhibitor that have the added risk of potential bone and joint effects.
My take, Tamoxitest CYP2D6 testing is ready for prime time. It’s a win-win for patient, physicians, and payers – reduced costs and improved outcomes!
Filed under: Personalized Medicine | Tagged: breast cancer, CYP, CYP2D6, Cytochrome, JAMA, Personalized Medicine, Pharmacogenetics, tamoxifen
